Journal of Clinical Oncology, Vol 12, 2471-2508, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

PURPOSE: Standard practice in protecting against chemotherapy- associated infection has been chemotherapy dose modification or dose delay, administration of progenitor-cell support, or selective use of prophylactic antibiotics. Therapy of chemotherapy-associated neutropenic fever or infection has customarily involved treatment with intravenous antibiotics, usually accompanied by hospitalization. The hematopoietic colony-stimulating factors (CSFs) have been introduced into clinical practice as additional supportive measures that can reduce the likelihood of neutropenic complications due to chemotherapy. Clinical benefit has been shown, but the high cost of CSFs has led to concern about their appropriate use. The American Society of Clinical Oncology (ASCO) wishes to establish evidence-based, clinical practice guidelines for the use of CSFs in patients who are not enrolled on clinical trials. METHODS: An expert multidisciplinary panel reviewed the clinical data documenting the activity of CSFs. For each common clinical situation, the Panel formulated a guideline to encourage reasonable use of CSFs to preserve effectiveness but discourage excess use when little marginal benefit is anticipated. Consensus was reached after critically appraising the available evidence. Guidelines were validated by comparing them with recommendations for CSF use developed in other countries and by several academic institutions. Outcomes considered in evaluating CSF benefit included duration of neutropenia, incidence of febrile neutropenia, incidence and duration of antibiotic use, frequency and duration of hospitalization, infectious mortality, chemotherapy dose-intensity, chemotherapy efficacy, quality of life, CSF toxicity, and economic impact. To the extent that these data were available, the Panel placed greatest value on survival benefit, reduction in rates of febrile neutropenia, decreased hospitalization, and reduced costs. Lesser value was placed on alterations in absolute neutrophil counts (ANC). CONCLUSIONS: CSFs are recommended in some situations, eg, to reduce the likelihood of febrile neutropenia when the expected incidence is > or = 40%; after documented febrile neutropenia in a prior chemotherapy cycle to avoid infectious complications and maintain dose-intensity in subsequent treatment cycles when chemotherapy dose-reduction is not appropriate; and after high-dose chemotherapy with autologous progenitor-cell transplantation. CSFs are also effective in the mobilization of peripheral-blood progenitor cells. Therapeutic initiation of CSFs in addition to antibiotics at the onset of febrile neutropenia should be reserved for patients at high risk for septic complications. CSF use in patients with myelodysplastic syndromes may be reasonable if they are experiencing neutropenic infections. Administration of CSFs after initial chemotherapy for acute myeloid leukemia does not appear to be detrimental, but clinical benefit has been variable and caution is advised. Available data support use of CSFs in pediatric cancer patients similar to that recommended for adult patients. Outside of clinical trials, CSFs should not be used concurrently with chemotherapy and radiation, or to support increasing chemotherapy dose-intensity. Further research is warranted as a means to improve the cost-effective administration of the CSFs and identify clinical predictors of infectious complications that may direct their use.

This article has been cited by other articles:

				M. R. Somerfield, K. Einhaus, K. L. Hagerty, M. C. Brouwers, J. Seidenfeld, and G. H. Lyman American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges J. Clin. Oncol., August 20, 2008; 26(24): 4022 - 4026. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

				N. M. Kuderer, D. C. Dale, J. Crawford, and G. H. Lyman Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review J. Clin. Oncol., July 20, 2007; 25(21): 3158 - 3167. [Abstract] [Full Text] [PDF]

				A. Dekker, S. Bulley, J. Beyene, L. L. Dupuis, J. J. Doyle, and L. Sung Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation J. Clin. Oncol., November 20, 2006; 24(33): 5207 - 5215. [Abstract] [Full Text] [PDF]

				C. M. Gutschalk, C. C. Herold-Mende, N. E. Fusenig, and M. M. Mueller Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Promote Malignant Growth of Cells from Head and Neck Squamous Cell Carcinomas In vivo Cancer Res., August 15, 2006; 66(16): 8026 - 8036. [Abstract] [Full Text] [PDF]

				X. L. Du, D. R. Lairson, C. E. Begley, and S. Fang Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From a Large Population-Based Cohort J. Clin. Oncol., December 1, 2005; 23(34): 8620 - 8628. [Abstract] [Full Text] [PDF]

				P. Papaldo, M. Lopez, P. Marolla, E. Cortesi, M. Antimi, E. Terzoli, P. Vici, C. Barone, G. Ferretti, S. Di Cosimo, et al. Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide J. Clin. Oncol., October 1, 2005; 23(28): 6908 - 6918. [Abstract] [Full Text] [PDF]

				O. A.C. Clark, G. H. Lyman, A. A. Castro, L. G.O. Clark, and B. Djulbegovic Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials J. Clin. Oncol., June 20, 2005; 23(18): 4198 - 4214. [Abstract] [Full Text] [PDF]

				E. Obermueller, S. Vosseler, N. E. Fusenig, and M. M. Mueller Cooperative Autocrine and Paracrine Functions of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in the Progression of Skin Carcinoma Cells Cancer Res., November 1, 2004; 64(21): 7801 - 7812. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, B. Lange, J. Beyene, and G. R. Buchanan Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials J. Clin. Oncol., August 15, 2004; 22(16): 3350 - 3356. [Abstract] [Full Text] [PDF]

				S. Smeland, A. K. Blystad, S. O. Kvaloy, I. M. Ikonomou, J. Delabie, G. Kvalheim, J. Hammerstrom, G. F. Lauritzsen, and H. Holte Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens Ann. Onc., July 1, 2004; 15(7): 1072 - 1078. [Abstract] [Full Text] [PDF]

				L. M. Wagner, C. A. Billups, W. L. Furman, B. N. Rao, and V. M. Santana Combined Use of Erythropoietin and Granulocyte Colony-Stimulating Factor Does Not Decrease Blood Transfusion Requirements During Induction Therapy for High-Risk Neuroblastoma: A Randomized Controlled Trial J. Clin. Oncol., May 15, 2004; 22(10): 1886 - 1893. [Abstract] [Full Text] [PDF]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				C. H. Takimoto and E. K. Rowinsky Dose-Intense Paclitaxel: Deja Vu All Over Again? J. Clin. Oncol., August 1, 2003; 21(15): 2810 - 2814. [Full Text] [PDF]

				M. V. Relling, J. M. Boyett, J. G. Blanco, S. Raimondi, F. G. Behm, J. T. Sandlund, G. K. Rivera, L. E. Kun, W. E. Evans, and C.-H. Pui Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment Blood, May 15, 2003; 101(10): 3862 - 3867. [Abstract] [Full Text] [PDF]

				V. C. G. Tjan-Heijnen, S. Caleo, P. E. Postmus, A. Ardizzoni, J. T. M. Burghouts, E. Buccholz, B. Biesma, T. Gorlia, R. Crott, G. Giaccone, et al. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923) Ann. Onc., February 1, 2003; 14(2): 248 - 257. [Abstract] [Full Text] [PDF]

				M. R. Baer, S. L. George, R. K. Dodge, K. L. O'Loughlin, H. Minderman, M. A. Caligiuri, J. Anastasi, B. L. Powell, J. E. Kolitz, C. A. Schiffer, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood, July 30, 2002; 100(4): 1224 - 1232. [Abstract] [Full Text] [PDF]

				C. Patte, A. Laplanche, A. I. Bertozzi, A. Baruchel, D. Frappaz, C. Schmitt, F. Mechinaud, B. Nelken, P. Boutard, and J. Michon Granulocyte Colony-Stimulating Factor in Induction Treatment of Children With Non-Hodgkin's Lymphoma: A Randomized Study of the French Society of Pediatric Oncology J. Clin. Oncol., January 15, 2002; 20(2): 441 - 448. [Abstract] [Full Text] [PDF]

				C. T. Kouroukis, G. P. Browman, R. Esmail, and R. M. Meyer Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma: A Systematic Review Ann Intern Med, January 15, 2002; 136(2): 144 - 152. [Abstract] [Full Text] [PDF]

				T. J. Smith and B. E. Hillner Ensuring Quality Cancer Care by the Use of Clinical Practice Guidelines and Critical Pathways J. Clin. Oncol., June 1, 2001; 19(11): 2886 - 2897. [Abstract] [Full Text] [PDF]

				H. Nelson, N. Petrelli, A. Carlin, J. Couture, J. Fleshman, J. Guillem, B. Miedema, D. Ota, and D. Sargent Guidelines 2000 for Colon and Rectal Cancer Surgery J Natl Cancer Inst, April 18, 2001; 93(8): 583 - 596. [Abstract] [Full Text] [PDF]

				L. B. Saltz, J.-Y. Douillard, N. Pirotta, M. Alakl, G. Gruia, L. Awad, G. L. Elfring, P. K. Locker, and L. L. Miller Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard Oncologist, February 1, 2001; 6(1): 81 - 91. [Abstract] [Full Text]

				R. Garcia-Carbonero, J. I. Mayordomo, M. V. Tornamira, M. Lopez-Brea, A. Rueda, V. Guillem, A. Arcediano, A. Yubero, F. Ribera, C. Gomez, et al. Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial J Natl Cancer Inst, January 3, 2001; 93(1): 31 - 38. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				S. Kojima, S. Hibi, Y. Kosaka, M. Yamamoto, M. Tsuchida, H. Mugishima, K. Sugita, H. Yabe, A. Ohara, and I. Tsukimoto Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia Blood, September 15, 2000; 96(6): 2049 - 2054. [Abstract] [Full Text] [PDF]

				C. F. Verschraegen, T. Sittisomwong, A. P. Kudelka, E. d. P. Guedes, M. Steger, T. Nelson-Taylor, M. Vincent, R. Rogers, E. N. Atkinson, and J. J. Kavanagh Docetaxel for Patients With Paclitaxel-Resistant Mullerian Carcinoma J. Clin. Oncol., July 14, 2000; 18(14): 2733 - 2739. [Abstract] [Full Text] [PDF]

				G. Michel, J. Landman-Parker, M. F. Auclerc, C. Mathey, T. Leblanc, E. Legall, P. Bordigoni, J. P. Lamagnere, F. Demeocq, Y. Perel, et al. Use of Recombinant Human Granulocyte Colony-Stimulating Factor to Increase Chemotherapy Dose-Intensity: A Randomized Trial in Very High-Risk Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., April 7, 2000; 18(7): 1517 - 1524. [Abstract] [Full Text] [PDF]

				G. Swanson, K. Bergstrom, E. Stump, T. Miyahara, and E. T. Herfindal Growth Factor Usage Patterns and Outcomes in the Community Setting: Collection Through a Practice-Based Computerized Clinical Information System J. Clin. Oncol., April 1, 2000; 18(8): 1764 - 1770. [Abstract] [Full Text] [PDF]

				C. L. Bennett, J. A. Weeks, M. R. Somerfield, J. Feinglass, and T. J. Smith Use of Hematopoietic Colony-Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines J. Clin. Oncol., November 1, 1999; 17(11): 3676 - 3681. [Abstract] [Full Text] [PDF]

				M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355. [Abstract] [Full Text] [PDF]

				N. Kalil and B. D. Cheson Chronic Lymphocytic Leukemia Oncologist, October 1, 1999; 4(5): 352 - 369. [Abstract] [Full Text]

				I. Ray-Coquard, A. Le Cesne, M. T. Rubio, J. Mermet, C. Maugard, A. Ravaud, C. Chevreau, C. Sebban, T. Bachelot, P. Biron, et al. Risk Model for Severe Anemia Requiring Red Blood Cell Transfusion After Cytotoxic Conventional Chemotherapy Regimens J. Clin. Oncol., September 1, 1999; 17(9): 2840 - 2840. [Abstract] [Full Text] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]

				A. Saven, C. Burian, J. Adusumalli, and J. A. Koziol Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia Blood, April 15, 1999; 93(8): 2471 - 2477. [Abstract] [Full Text] [PDF]

				C. E. Desch, A. B. Benson III, T. J. Smith, P. J. Flynn, C. Krause, C. L. Loprinzi, B. D. Minsky, N. J. Petrelli, D. G. Pfister, and M. R. Somerfield Recommended Colorectal Cancer Surveillance Guidelines by the American Society of Clinical Oncology J. Clin. Oncol., April 1, 1999; 17(4): 1312 - 1312. [Abstract] [Full Text] [PDF]

				M. Foote The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice? Oncologist, October 1, 1998; 3(5): 365 - 368. [Full Text]

				Integrating Economic Analysis Into Cancer Clinical Trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook J Natl Cancer Inst Monographs, August 1, 1998; 1998(24): 1 - 28. [Full Text]

				S. Scheding, J. E. Media, and A. Nakeff Influence of rhG-CSF Scheduling on Megakaryocytopoietic Recovery following 5-Fluorouracil-Induced Hematotoxicity in Splenectomized B6D2F1 Mice Stem Cells, March 1, 1998; 16(2): 144 - 151. [Abstract] [Full Text]

				D. Armstrong and S. O'Reilly Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity Oncologist, February 1, 1998; 3(1): 4 - 10. [Abstract] [Full Text]

				J. A. Talcott Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care? Oncologist, December 1, 1997; 2(6): 365 - 373. [Abstract] [Full Text] [PDF]

				F. Cabanillas, L. C. Hartmann, V. J. Suman, and The North Central Cancer Treatment Group Granulocyte Colony-Stimulating Factor in Afebrile Patients with Neutropenia N. Engl. J. Med., October 30, 1997; 337(18): 1319 - 1320. [Full Text]

				P. Gupta, K. Welte, H. Riehm, C.-H. Pui, and W. E. Evans Granulocyte Colony-Stimulating Factor in Children with Acute Lymphoblastic Leukemia N. Engl. J. Med., October 30, 1997; 337(18): 1320 - 1321. [Full Text]

				P. Anderlini, M. Korbling, D. Dale, A. Gratwohl, N. Schmitz, D. Stroncek, C. Howe, S. Leitman, M. Horowitz, E. Gluckman, et al. Allogeneic Blood Stem Cell Transplantation: Considerations for Donors Blood, August 1, 1997; 90(3): 903 - 908. [Abstract] [Full Text] [PDF]

				K. Geissler, E. Koller, E. Hubmann, D. Niederwieser, W. Hinterberger, D. Geissler, P. Kyrle, P. Knobl, I. Pabinger, R. Thalhammer, et al. Granulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia --- A Randomized Phase-III Study Blood, July 15, 1997; 90(2): 590 - 596. [Abstract] [Full Text] [PDF]

				L. C. Hartmann, L. K. Tschetter, T. M. Habermann, L. P. Ebbert, P. S. Johnson, J. A. Mailliard, R. Levitt, V. J. Suman, T. E. Witzig, H.S. Wieand, et al. Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia N. Engl. J. Med., June 19, 1997; 336(25): 1776 - 1780. [Abstract] [Full Text] [PDF]

				C.-H. Pui, J. M. Boyett, W. T. Hughes, G. K. Rivera, M. L. Hancock, J. T. Sandlund, T. Synold, M. V. Relling, R. C. Ribeiro, W. M. Crist, et al. Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia N. Engl. J. Med., June 19, 1997; 336(25): 1781 - 1787. [Abstract] [Full Text] [PDF]

				R. Carr and N. Modi Haemopoietic colony stimulating factors for preterm neonates Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1997; 76(2): 128F - 133. [Full Text]

				B. D. Cheson The Myelodysplastic Syndromes Oncologist, February 1, 1997; 2(1): 28 - 39. [Abstract] [Full Text] [PDF]

				J. O. Moore, R. K. Dodge, P. C. Amrein, J. Kolitz, E. J. Lee, B. Powell, S. Godfrey, F. Robert, and C. A. Schiffer Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022  Blood, February 1, 1997; 89(3): 780 - 788. [Abstract] [Full Text] [PDF]

				D. J. Kuter Thrombopoietin: Biology and Clinical Applications Oncologist, February 1, 1996; 1(1): 98 - 106. [Abstract] [Full Text] [PDF]

				B. Brockstein and S. Williams High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow Stem Cells, January 1, 1996; 14(1): 79 - 89. [Abstract]